Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
2001 1
2002 1
2009 3
2010 4
2011 6
2012 3
2013 1
2014 2
2015 2
2016 3
2017 6
2018 2
2019 4
2020 6
2021 8
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.
Abdominal pain in adults with cystic fibrosis.
Nash EF, Ohri CM, Stephenson AL, Durie PR. Nash EF, et al. Eur J Gastroenterol Hepatol. 2014 Feb;26(2):129-36. doi: 10.1097/MEG.0000000000000011. Eur J Gastroenterol Hepatol. 2014. PMID: 24366450 Review.
Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.
Hoo ZH, Coates E, Maguire C, Cantrill H, Shafi N, Nash EF, McGowan A, Bourke SJ, Flight WG, Daniels TV, Nightingale JA, Allenby MI, Curley R, Wildman MJ. Hoo ZH, et al. Among authors: nash ef. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2219-2222. doi: 10.1007/s10096-018-3358-8. Epub 2018 Aug 18. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30121804 No abstract available.
Non-invasive ventilation.
Nash EF. Nash EF. Thorax. 2002 Oct;57(10):919. doi: 10.1136/thorax.57.10.919-a. Thorax. 2002. PMID: 12324683 Free PMC article. No abstract available.
Novel detection of specific bacterial quorum sensing molecules in saliva: Potential non-invasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosis.
Webb K, Cámara M, Zain NMM, Halliday N, Bruce KD, Nash EF, Whitehouse JL, Knox A, Forrester D, Smyth AR, Williams P, Fogarty A, Barr HL. Webb K, et al. Among authors: nash ef. J Cyst Fibros. 2022 Jul;21(4):626-629. doi: 10.1016/j.jcf.2021.08.030. Epub 2021 Sep 11. J Cyst Fibros. 2022. PMID: 34518117
46 results